2 results
Approved WMORecruiting
Currently, there are no curative treatment options for patients with Waldenstrom*s macroglobulinemia (WM) and there is no consensus on standard first line or relapse treatment. The proteasome inhibitor bortezomib has shown efficacy in WM, but is…
Approved WMOPending
Objective: Primary Aim (PHASE 1):To determine the prevalence of RLS in women with ALD.Secondary Aim (PHASE 2):To determine whether in a blinded crossover study a 8-week pramipexole treatment course will significantly reduce RLS symptoms compared to…